Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.

Detaljer

Författare
  • Eva Herweijer
  • Amy Leval
  • Alexander Ploner
  • Sandra Eloranta
  • Julia Fridman Simard
  • Joakim Dillner
  • Eva Netterlid
  • Pär Sparén
  • Lisen Arnheim-Dahlström
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Miljömedicin och yrkesmedicin
  • Dermatologi och venereologi

Nyckelord

Originalspråkengelska
Sidor (från-till)597-603
TidskriftJAMA: The Journal of the American Medical Association
Volym311
Utgåva nummer6
StatusPublished - 2014
PublikationskategoriForskning
Peer review utfördJa